Home Your basket
• Dehiscence of the anterio...
   Price 8.50 €
• Surgical procedure in fir...
   Price 8.50 €
• Transsexualism: From diag...
   Price 10.50 €
• Scaling properties of the...
   Price 5.50 €
• Anterior cerebrospinal fl...
   Price 10.00 €
• Overlay versus underlay t...
   Price 10.50 €
• The pedicle superficial t...
   Price 10.50 €
• Botulinum toxin and rejuv...
   Price 10.50 €
• Combined induction chemot...
   Price 10.50 €
• Smile "forced" smile vers...
   Price 10.50 €
• Aesthetic profiloplasty: ...
   Price 10.50 €
• Aneurysmal bone cyst of t...
   Price 5.50 €
• Conference : Medicine of ...
   Price 5.50 €
• Identification and locali...
   Price 8.50 €
• Evolution of facial nerve...
   Price 10.50 €
• Tonsillitis tuberculous s...
   Price 8.50 €
• Post-operative complicati...
   Price 10.50 €
• Thyroid papillary microca...
   Price 10.50 €
• Temporomandibular dysfunc...
   Price 10.50 €
• Solitary myofibroma of th...
   Price 5.50 €
• Unilateral endolymphatic ...
   Price 10.50 €
• Multi-factorial analysis ...
   Price 10.50 €
• The ultra-rapid cinematog...
   Price 10.50 €
• Persistent stapedial arte...
   Price 5.50 €
• Vestibular neuritis: Eval...
   Price 14.00 €
• Medicamentous toxic heari...
   Price 5.50 €
• Otologic surgery in HIV-i...
   Price 8.50 €
• Hearing aids rehabilitati...
   Price 12.50 €
• Parathyroid carcinoma: di...
   Price 5.50 €
• Rhinolithiasis: Review ab...
   Price 5.50 €
• Abscess tonsillectomy for...
   Price 10.50 €
• Otogenic pneumocephalus: ...
   Price 5.50 €
• Newborn and infant nasal ...
   Price 5.50 €
• Association of Bezold’s a...
   Price 8.50 €
• Myringoplasties for anter...
   Price 10.50 €
• Vestibular-evoked myogeni...
   Price 10.50 €
• Sphenochoanal polyp: Repo...
   Price 5.50 €

Total Order 326.50 €

contents
2019
   N# 1 |
2018
   N# 1 | 2 | 3 | 4 | 5 |
2017
   N# 1 | 2 | 3 | 4 | 5 |
2016
   N# 1 | 2 | 3 | 4 | 5 |
2015
   N# 1 | 2 | 3 | 4 | 5 |
2014
   N# 1 | 2 | 3 | 4 | 5 |
2013
   N# 1 | 2 | 3 | 4 | 5 |
2012
   N# 1 | 2 | 3 | 4 | 5 |
2011
   N# 1 | 2 | 3 | 4 | 5 |
2010
   N# 1 | 2 | 3 | 4 | 5 |
2009
   N# 1 | 2 | 3 | 4 | 5 |
2008
   N# 1 | 2 | 3 | 4 | 5 |
2007
   N# 1 | 2 | 3 | 4 | 5 |
2006
   N# 1 | 2 | 3 | 4 | 5 |
2005
   N# | 1 | 2 | 3 | 4 | 5 |
2004
   N# 1 | 2 | 3 | 4 | 5 |
2003
   N# 1 | 2 | 3 | 4 | 5 |
2002
   N# 1 | 2 | 3 | 4 | 5 |
2001
   N# 1 | 2 | 3 | 4 | 5 |
2000
   N# | 1 | 2 | 3 | 4 | 5 |
1999
   N# 1 | 2 | 3 | 4 | 5 |
1998
   N# 1 | 2 | 3 | 5 |
1997
   N# 1 | 2 | 3 | 4 | 5 |
1996
   N# 4 | 5 |

Click on the number of the review to see the content
Teaching bulletin CME
List of all teaching bulletins CME.
Editor reading committee
Editor reading committee.
To publish...
Instructions for authors
Archives Press and Books
Select of books and press articles.
Mailing list
News information letter.
Subscription prices


If you wish to adjust the size of the displayed characters, click in the high menu on "Your account" and choose the desired size.



  Contents > Previous page > Article detail print Order
o Issue N# 3 - 2017 o

OTOLOGY

Observational study to assess the effect of Audistim® on the quality of life of patients presenting with chronic tinnitus


Authors : Frachet B, Portmann D, Allaert FA. (Paris, Bordeaux, Dijon)

Ref. : Rev Laryngol Otol Rhinol. 2017;138,3:79-85.

Article published in english
Downloadable PDF document english



Summary : Objectives: To evaluate the improvement of symptoms, quali­ty of life, psychological stress and sleep quality of patients suffering from chronic tinnitus after a 3 months intake of Audistim®. Methods: Observational study of Audistim® by ENT doctors in patients consulting them for chronic tinnitus. Evaluation criterion: THI quality of life score, PSQI sleep score, MSP-9 Stress score. Patients were examined at baseline and at 3 months. Results: 314 patients aged 54.1 ± 13.0 years and suffering from tinnitus since 5.8 ± 7.3 years were included in the study. At the end of the 3 months, patients’ quality of life chan­­ged from 44.6 ± 23.4 to 26.7 ± 18.7 corresponding to an impro­vement of 40.1% (< 0.0001), subjects’ stress from 38.5 ± 13.3 to 30.1 ± 10.8 to 3 months corresponding to an improve­ment of 21.8% (<0.0001) and sleep quality of 8.4 ± 4.5 to 5.4 ± 3.2 corresponding to an improvement of 35.7%. Quality of life improvement was significantly correlated with stress impro­vement (r: 0.77 (p< 0.0001) and sleep (r: 0.70 (p< 0.0001). Tinnitus were improved in 70.0% of patients according to doc­tors, and in 69% of them according to the patients themselves. 2.8% of patients experienced adverse events, essentially diges­tive, none of which was judged by doctors as imputable to the intake of Audistim®. Conclusion: The original composition of Audistim® combining several active ingredients used to control tinnitus gives rise to clear improvements in the quality of life, stress and sleep of the patients experiencing tinnitus and provides them satisfaction without the risk of adverse events.


Price : 14.00 €      order
|


Subscribe online - Pay by credit card!


© Copyright 1999-2024 - Revue de Laryngologie   Réalisation - Hébergement ELIDEE